Eisai (4523.T)

Executive Summary

Eisai Co., Ltd. is a Japanese pharmaceutical leader with a strong presence in neurology and oncology, operating under a 'human health care' philosophy. The company has successfully commercialized drugs like Aricept (donepezil) for Alzheimer's and Lemborexant for insomnia, and its pipeline includes late-stage assets such as lecanemab (Leqembi) for Alzheimer's, co-developed with Biogen. Despite facing generic competition for mature products, Eisai's strategic focus on innovative therapies and global health equity positions it for growth. The company's solid product portfolio and ongoing clinical trials in areas like Alzheimer's and sleep disorders underpin its medium-term revenue prospects.

Upcoming Catalysts (preview)

• Q4 2026Lecanemab (Leqembi) label expansion in the EU and Japan for early Alzheimer's disease80% success
• Q2 2027Phase 3 data readout for Lemborexant in delayed sleep phase syndrome (DSPS)60% success
• Q3 2027Potential new drug application for Lemborexant in DSPS and other sleep disorders50% success